No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Up to 50% of a neostigmine dose is excreted unchanged via the kidneys. As other non-renal elimination mechanisms are involved, significant interactions via competition with emtricitabine or tenofovir for active renal transport are unlikely.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking